Beljanski, Vladimir <br/><br/>
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.  [electronic resource] 

 -  Investigational new drugs  Dec 2011 
 - 1132-42 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-010-9452-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--administration & dosage<br/>Adenocarcinoma--drug therapy<br/>Administration, Oral<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Benzenesulfonates--administration & dosage<br/>Caspase 3--metabolism<br/>Caspase 7--metabolism<br/>Catechols--administration & dosage<br/>Cell Line, Tumor<br/>DNA Fragmentation--drug effects<br/>Drug Synergism<br/>Female<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Mice<br/>Mice, SCID<br/>Niacinamide--analogs & derivatives<br/>Pancreatic Neoplasms--drug therapy<br/>Phenylurea Compounds<br/>Phosphotransferases (Alcohol Group Acceptor)--antagonists & inhibitors<br/>Pyridines--administration & dosage<br/>Sorafenib<br/>Xenograft Model Antitumor Assays